Chien-Hsin Chen1, Mao-Chih Hsieh2, Wilson T Lao3, En-Kwang Lin1, Yen-Jung Lu1, Szu-Yuan Wu4,5,6. 1. Department of Colorectal Surgery, Wan Fang Hospital, Taipei Medical University Taipei, Taiwan. 2. Department of General Surgery, Wan Fang Hospital, Taipei Medical University Taipei, Taiwan. 3. Department of Radiology, Wan Fang Hospital, Taipei Medical University Taipei, Taiwan. 4. Department of Radiation Oncology, Wan Fang Hospital, Taipei Medical University Taipei, Taiwan. 5. Institute of Clinical Science, Zhongshan Hospital, Fudan University Shanghai 200032, China. 6. Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan.
Abstract
BACKGROUND AND OBJECTIVES: To investigate whether multidisciplinary team (MDT) intervention is associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis (CRA-LLM). METHODS: We enrolled 161 consecutive patients with histologically confirmed CRA-LLM at Taipei Medical University-Wan Fang Hospital between January 2007 and December 2017. In total, 75 patients with CRA-LLM received MDT intervention, and 86 patients did not receive MDT intervention. To evaluate prognostic factors for overall death, we performed univariate and multivariate Cox regression analyses of the overall death rate in all patients. Overall survival rates were calculated using the Kaplan-Meier method, and Kaplan-Meier survival curves were compared using the log-rank test (P < .001). RESULTS: A multivariate Cox regression analysis of the overall death rate in patients with CRA-LLM showed that age ≤ 65 years, systemic chemotherapy, curative-intent treatments, and MDT intervention are strong prognostic factors. The adjusted hazard ratio of death risk for age ≤ 65 years, systemic chemotherapy, curative-intent treatments, and MDT intervention were 0.60 (95% confidence interval [CI], 0.40-0.92; P = .019), 0.19 (95% CI, 0.12-0.32; P = .001), 0.25 (95% CI, 0.13-0.50; P = .001), and 0.40 (95% CI, 0.25-0.65; P = .001), respectively. The 3-year overall survival rates in patients with CRA-LLM receiving MDT intervention and not receiving MDT intervention were 48.75% and 24.21%, respectively. CONCLUSION: MDT intervention is associated with improved survival for patients with CRA-LLM.
BACKGROUND AND OBJECTIVES: To investigate whether multidisciplinary team (MDT) intervention is associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis (CRA-LLM). METHODS: We enrolled 161 consecutive patients with histologically confirmed CRA-LLM at Taipei Medical University-Wan Fang Hospital between January 2007 and December 2017. In total, 75 patients with CRA-LLM received MDT intervention, and 86 patients did not receive MDT intervention. To evaluate prognostic factors for overall death, we performed univariate and multivariate Cox regression analyses of the overall death rate in all patients. Overall survival rates were calculated using the Kaplan-Meier method, and Kaplan-Meier survival curves were compared using the log-rank test (P < .001). RESULTS: A multivariate Cox regression analysis of the overall death rate in patients with CRA-LLM showed that age ≤ 65 years, systemic chemotherapy, curative-intent treatments, and MDT intervention are strong prognostic factors. The adjusted hazard ratio of death risk for age ≤ 65 years, systemic chemotherapy, curative-intent treatments, and MDT intervention were 0.60 (95% confidence interval [CI], 0.40-0.92; P = .019), 0.19 (95% CI, 0.12-0.32; P = .001), 0.25 (95% CI, 0.13-0.50; P = .001), and 0.40 (95% CI, 0.25-0.65; P = .001), respectively. The 3-year overall survival rates in patients with CRA-LLM receiving MDT intervention and not receiving MDT intervention were 48.75% and 24.21%, respectively. CONCLUSION:MDT intervention is associated with improved survival for patients with CRA-LLM.
Authors: Chyke A Doubeni; Adeyinka O Laiyemo; Jacqueline M Major; Mario Schootman; Min Lian; Yikyung Park; Barry I Graubard; Albert R Hollenbeck; Rashmi Sinha Journal: Cancer Date: 2012-01-03 Impact factor: 6.860
Authors: S Salah; K Watanabe; S Welter; J S Park; J W Park; J Zabaleta; F Ardissone; J Kim; M Riquet; K Nojiri; M Gisabella; S Y Kim; K Tanaka; B Al-Haj Ali Journal: Ann Oncol Date: 2012-04-29 Impact factor: 32.976
Authors: Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245
Authors: James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544